Skip to main content

TNF inhibitor

    RT @doctorRBC: Drug retention of TNFi vs. secukinumab in AxSpA pts
    Abs#911
    ⭐️46% discontinued either treatment
    ⭐ï
    2 years 3 months ago
    Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX
    RT @swethaann23: ⭐️Prevalent drug utilization was not related to enthesitis activity
    ⭐️Prevalent use of cDMARDs
    2 years 3 months ago
    ⭐️Prevalent drug utilization was not related to enthesitis activity ⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i ⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
    Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annu
    2 years 3 months ago
    Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting. https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI
    RT @drdavidliew: Put those two RF together (essentially nailing down RA pts at risk of cancer):

    age >65 or ever smok
    2 years 3 months ago
    Put those two RF together (essentially nailing down RA pts at risk of cancer): age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30) age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24) neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55) #ACR21 @RheumNow https://t.co/Uvr4wBhFVF
    Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…
    RT @RichardPAConway: Therapeutic drug monitoring ⬆️ infliximab efficacy in RCT. 17.6% improvement in sustained disea
    2 years 3 months ago
    Therapeutic drug monitoring ⬆️ infliximab efficacy in RCT. 17.6% improvement in sustained disease control. Consistent across all rheumatic and non-rheumatic diseases. Abstr#1946 #ACR21 @RheumNow https://t.co/D1Ppb58fB8
    RT @RichardPAConway: ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared
    2 years 3 months ago
    ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
    RT @drdavidliew: ORAL Surveillance: MACE and malignancy are getting all the attention...

    but did you know that non-zost
    2 years 3 months ago
    ORAL Surveillance: MACE and malignancy are getting all the attention... but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis? #ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j